Merz has reported that new XEOMIN (Botulinum neurotoxin type A) is now available in Canada. The drug would be prescribed to patients with Blepharospasm, Cervical Dystonia and Post-Stroke Spasticity.
The company said that it is confident that physicians will find new XEOMIN to be a neurotoxin option worth considering for many of their patients.
Merz specializes in the research and marketing of drugs for the treatment of neurological and psychiatric diseases. The company works in the field of Alzheimer’s research and developed the first drug for the treatment of moderate to severe stages of Alzheimer’s disease. In the neurological sector, Merz also offers drugs for the treatment of Parkinson’s, depression and dystonia.